Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EBIT (2021 - 2026)

HeartSciences filings provide 6 years of EBIT readings, the most recent being -$1.9 million for Q1 2026.

  • On a quarterly basis, EBIT rose 18.66% to -$1.9 million in Q1 2026 year-over-year; TTM through Jan 2026 was -$7.8 million, a 6.2% increase, with the full-year FY2025 number at -$8.4 million, down 32.46% from a year prior.
  • EBIT hit -$1.9 million in Q1 2026 for HeartSciences, up from -$2.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$1.1 million in Q1 2022 to a low of -$2.4 million in Q1 2025.
  • Median EBIT over the past 5 years was -$1.9 million (2025), compared with a mean of -$1.7 million.
  • Biggest five-year swings in EBIT: crashed 112.04% in 2022 and later increased 19.17% in 2023.
  • HeartSciences' EBIT stood at -$1.8 million in 2022, then grew by 11.55% to -$1.6 million in 2023, then dropped by 26.44% to -$2.0 million in 2024, then dropped by 4.45% to -$2.1 million in 2025, then grew by 6.97% to -$1.9 million in 2026.
  • The last three reported values for EBIT were -$1.9 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.9 million (Q3 2025) per Business Quant data.